Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: “It’s time to go back on offense,” Lechleiter said in a recent interview. New treatments for diabetes and cancer now awaiting approval and increased sales of animal-health products and drugs in China and Japan are some of the aggressive moves he has in mind. He is also counting on a robust success rate among three dozen other experimental drugs now in mid- and late-stage trials, including a cancer drug called ramucirumab. “We’re on the cusp of launching products in cancer and diabetes, two therapeutic areas where we’re well established and where we have built out the infrastructure we need,” Lechleiter said. “And we believe that’s going to be the beginning of our return to growth.”  Skeptical investors only now appear to be catching on to Lilly’s potential upside. After rising only 3 percent in 2013, badly underperforming a 27 percent average advance for other large drugmakers, the stock is up 6 percent this month. “Instead of having to play defense and manage through this difficult patent cliff, the company will be able to use additional cash flow to invest in its pipeline, to partner with others or make bolt-on acquisitions,” said Atlantic Equities analyst Richard Purkiss. “The outlook is much brighter, and they’ll try to get that message across in coming months.”  Lilly, which reports quarterly and 2013 results on Thursday, has forecast earnings of $2.77 to $2.85 per share this year, the final and worst year of its patent cliff. That’s 41 percent less than 2010. Lilly last year sought U.S. approvals for four drugs, three of which Lechleiter said could be approved in 2014: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of diabetes, which is closely linked to obesity. Analysts have forecast annual sales of more than $650 million for ramucirumab, saying sales could be far higher if the drug also wins approval for cancers of the colon, lung or liver. But they caution that the diabetes drugs may have a hard time competing against existing options. Lechleiter said Lilly plans to seek approval of necitumumab for squamous-cell lung cancer this year. The medicine, like ramucirumab, was acquired by Lilly through its $6.5 billion purchase of ImClone Systems in 2008. If approved, necitumumab could capture eventual annual sales of more than $1 billion, analysts say. Such sales could make a big difference for Lilly, whose annual revenue of $20 billion is far lower than Big Pharma rivals like Pfizer Inc and Merck & Co. In the meantime, Lilly is testing nearly 40 medicines in mid- and late stage studies, compared with only 7 in those stages of development a decade ago. They include new treatments for cholesterol, psoriasis, lupus, rheumatoid arthritis and Alzheimer’s disease. Animal health unit Elanco, with annual sales of about $2 billion, is thriving as Lilly introduces new products and has expanded the business in China and other fast-growing markets. Many analysts are wary, however, of the company’s ability to win approvals of prescription drugs because it has not launched any major products in recent years and has suffered setbacks in clinical trials, including ramucirumab’s failure to delay progression of breast cancer. Of 20 analysts tracked by Thomson Reuters, 12 have hold or sell ratings on Lilly, versus 8 with buy ratings. Lilly shares trade at 19 times expected 2014 per-share earnings, compared to a price-to-earnings ratio of 14.6 for other large drugmakers. That could be more a reflection of the company’s poor earnings this year than excitement about the stock. “We believe that overall the pipeline will disappoint investors,” said Alex Arfaei of BMO Capital Markets in a research note, citing low sales expectations for ramucirumab and the new diabetes drugs. When Lilly’s Zyprexa was confronted with cheaper generic treatments for schizophrenia in October 2011, it faced one of the industry’s steepest patent cliffs ever, quickly losing 80 percent of its onetime $5 billion in annual sales. Similarly precipitous declines are expected for Cymbalta, Lilly’s $5 billion-a-year antidepressant, which lost U.S. patent protection last month, and for blockbuster osteoporosis treatment Evista, which goes generic in March. Many other large drugmakers, when faced with patent expirations and earnings declines of lesser scope, have resorted to megamergers to cushion the blow from generics and prop up earnings with cost savings. Huge layoffs, sapped morale and poor track records in introducing new drugs are more common results. Pfizer Inc stands out, having snapped up U.S. rivals Warner-Lambert, Pharmacia and Wyeth since 2000. Lechleiter, who began his career at Lilly in 1979 as a senior organic chemist, has steadfastly spurned any suggestion of a big merger: “It’s never entered our minds, and we remain adamantly opposed.”  John Boris, an analyst for Suntrust Robinson Humphrey, said he expects Lilly earnings to grow an average of 10 percent a year between 2015 and 2020, which would make it second to Bristol-Myers Squibb Co in profit growth over that period. Atlantic Equities’ Purkiss said he anticipates Lilly will deliver industry-topping earnings growth in the “mid-teens” percentage range in 2015, 2016 and 2017. “The sentiment has been very negative on Lilly, but it looks like it will go from one of the most growth-starved to the fastest growing of the major U.S. drugmakers and the European players,” Purkiss said. By avoiding a disruptive megamerger, Lilly has allowed itself to press ahead with ambitious research, said Barclays analyst Tony Butler. He said to date the company has met long-term sales and earnings forecasts it provided in 2009 - before patents went over the cliff - while maintaining its generous dividend, with a current yield of 3.6 percent. “At the time, the market was incredibly skeptical about Lilly’s ability to fund its dividend and to have enough remaining cash flow to fund its business,” said Butler. “Lilly proved everybody wrong.”  (This story has been refiled to change second subhead) Claim: Lilly CEO: 'It's time to go back on offense'.

Ex Output:
After three years of seeing major drugs like Zyprexa for schizophrenia lose patent protection and wipe away billions of dollars in revenue, Eli Lilly and Co Chief Executive Officer John Lechleiter wants to change the game plan.


Ex Input:
Paragraph: U.S. Marines of Weapons Company, 1st Battalion, 3rd Marines are silhouetted against the sunset during a joint patrol with Afghan National Army (ANA) soldiers along Helmand river near the Camp Gorgak in Helmand province, southern Afghanistan, July 3, 2011. REUTERS/Shamil Zhumatov The study, published in the Archives of Pediatrics and Adolescent Medicine, analyzed medical records of 307,520 children of active-duty Army personnel, aged 5 to 17 years old. It found almost 17 percent of them exhibited mental health problems. “Children of parents who spent more time deployed between 2003 and 2006 fared worse than children whose parents were deployed for a shorter duration,” the study’s researchers wrote. The lead researcher was Alyssa Mansfield, who was at the University of North Carolina at Chapel Hill at the time the study was conducted. The U.S. Army reported some 562,000 members in active duty and more than 570,000 children of such members in 2010. Just under two-thirds of all active-duty servicemen and women were married and 15 percent were raising children as single parents. The children whose parents deployed at least once, for an average of 11 months, as part of the U.S. Operation Iraqi Freedom or Operation Enduring Freedom in Afghanistan were especially likely to suffer from adjustment, behavioral, depressive or stress disorders than those whose parents never went to war, the study found. Boys were more likely to have mental health problems than girls, according to the report, which reviewed records for patients cared for at military medical facilities and at civilian facilities using military medical insurance. “We used to think about deployment as a single experience: I go, I’m away, it’s difficult and then I come back. Well, it’s a way of life in the military that deployments continue to occur and families have to manage the consequences,” said Dr. Stephen Cozza, psychiatry professor at the Uniformed Services University of the Health Sciences. Cozza has studied the issue and wrote an editorial accompanying the report. “These are consequences that aren’t necessarily short-term,” he said. The challenges don’t necessarily end with the final return home, he said, as soldiers may bring back their own mental health issues which affect relationships with their children. Claim: Mental problems of soldiers' kids tied to wars.

Ex Output:
The longer U.S. soldiers were deployed in Iraq or Afghanistan, the more likely their children would be diagnosed with mental health problems, according to a study published Monday.


Ex Input:
Paragraph: Department CEO Danette Smith made the pronouncement at a Lincoln news conference Monday while discussing her department’s efforts to better serve the teenage girls sent to the Geneva center that she emptied last week. Two dozen female juvenile offenders were moved to the boys center in Kearney after department officials learned the girls’ buildings in Geneva had fire hazards, holes in walls and mold and water damage. Staffers are discussing leasing a 20-bed portion at the Lancaster County Youth Services Center, Smith said. Discussions with the county are still preliminary, but she said the center could house the youths there, providing education, case management, probation and therapeutic recreation and transition services. The department is talking to various groups about addressing the needs of juvenile offenders, Smith said. “The department has an obligation to the youth we serve, and we are committed to making the necessary changes to provide an environment that is safe, supportive and gives youth the opportunity to thrive as they make the transition into adulthood,” she said. Regarding the troubled Geneva center, Smith said work has begun to fix the LaFlesche Cottage, a building that has been awaiting sewer line repairs since spring, and to assess what could be done to the other three residential buildings to make them usable. The campus in rural, central Nebraska serves as a rehabilitation center for girls ages 14-18 who have broken the law and been rejected by other private treatment facilities. The problems came to a head two weeks ago, when one girl damaged the sprinkler system in one of the four residential cottages. The girls moved to the boys center in Kearney have mental health services and case management support available there, as well as physicians who can manage medications, Smith said. Claim: Nebraska eyes county facility to treat juvenile offenders.

Ex Output:

Lancaster County officials and the state of Nebraska are discussing a way to provide intensive behavioral health services to juvenile offenders who need the help, the head of the state Health and Human Services Department said.